• 1
    Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
  • 2
    Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012; 107: 359-364.
  • 3
    Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML. The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer. 1999; 85: 485-491.
  • 4
    Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011; 29: 4175-4180.
  • 5
    National Cancer Institute. SEER Quality Improvement. Accessed February 24, 2012.
  • 6
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2010 Sub (1973-2008 varying) - Linked To County Attributes - Total U.S., 1969-2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Released April 2011. Updated October 28, 2011, based on the November 2010 submission.
  • 7
    National Cancer Institute. Surveillance Research Program, National Cancer Institute SEER*Stat software. Version 7.0.5. Released September 29, 2011.
  • 8
    Caloglu M, Yurut-Caloglu V, Karagol H, Bayir-Angin G, Turan FN, Uzal C. Prognostic factors other than the performance status and age for glioblastoma multiforme: a single-institution experience. J BUON. 2009; 14: 211-218.
  • 9
    Sant M, Minicozzi P, Lagorio S, Børge Johannesen T, Marcos-Gragera R, Francisci S; the EUROCARE Working Group. Survival of European patients with central nervous system tumors. Int J Cancer. 2011; doi:10.1002/ijc.26335.
  • 10
    Barnholtz-Sloan JS, Maldonado JL, Williams VL, et al. Racial/ethnic differences in survival among elderly patients with a primary glioblastoma. J Neurooncol. 2007; 85: 171-180.
  • 11
    Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer. 2003; 98: 603-609.
  • 12
    Chang SM, Barker FG 2nd. Marital status, treatment, and survival in patients with glioblastoma multiforme: a population based study. Cancer. 2005; 104: 1975-1984.
  • 13
    Kreth FW, Berlis A, Spiropoulou V, et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer. 1999; 86: 2117-2123.
  • 14
    Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011; 115: 3-8.
  • 15
    Taffs RE. Checking the proportional hazard assumption with Kaplan-Meier survival estimates. JMPer Cable. Fall 1997;( 5): 18-20.
  • 16
    Lee Y, Scheck AC, Cloughesy TF, et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics. 2008; 1: 52.
  • 17
    Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-466.
  • 18
    Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010; 16: 2443-2449.
  • 19
    Kraus JA, Wenghoefer M, Schmidt MC, et al. Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. J Neurol. 2000; 247: 455-460.
  • 20
    McCarthy BJ, Propp JM, Davis FG, Burger PC. Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology. 2008; 30: 34-44.